Celyad Oncology H1 FY26 net loss narrows to €1.2 million; operating loss narrows to €1.2 million
Bitget2026/09/23 19:31- Celyad Oncology posted a net loss of €1.2 million for the first half, narrowing from €3.7 million a year earlier.
- Operating loss narrowed to €1.2 million from €3.7 million, while employee benefit expense fell 71.43% to €0.4 million.
- Other operating expenses dropped 64% to €1 million, and net cash used in operations decreased 54.55% to €1.5 million.
- Cash and cash equivalents stood at €0.1 million at June 30, and a €0.5 million capital increase on July 16 strengthened liquidity.
- The group expects existing cash and cash equivalents to fund operating and capital expenditures into 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
